VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not demonstrated significant clinical benefit in patients with prostate cancer. To identify additional immune inhibitory pathways in the prostate tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors fr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nat Med
Asıl Yazarlar: Gao, Jianjun, Ward, John F, Pettaway, Curtis A, Shi, Lewis Z, Subudhi, Sumit K, Vence, Luis M, Zhao, Hao, Chen, Jianfeng, Chen, Hong, Efstathiou, Eleni, Troncoso, Patricia, Allison, James P, Logothetis, Christopher J, Wistuba, Ignacio I, Sepulveda, Manuel A, Sun, Jingjing, Wargo, Jennifer, Blando, Jorge, Sharma, Padmanee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466900/
https://ncbi.nlm.nih.gov/pubmed/28346412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4308
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller